Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Pharmaxis Ltd ( (AU:SNT) ) is now available.
Syntara Limited has appointed Mr. Cameron Billingsley as the new Company Secretary, replacing Mr. David McGarvey who has resigned after over 20 years of service. This leadership change marks a significant transition in the company’s administrative framework as it continues to focus on developing innovative treatments for serious health conditions, potentially impacting its industry positioning and stakeholder relationships.
More about Pharmaxis Ltd
Syntara Limited is a clinical stage drug development company specializing in targeting extracellular matrix dysfunction. It uses expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions related to inflammation and fibrosis. The company is managing multiple clinical studies, including phase 2 studies for diseases with high unmet needs, and is advancing its drug candidates for various fibrotic and inflammatory diseases. Syntara has also developed two respiratory products, Bronchitol and Aridol, which it sold in 2023.
YTD Price Performance: -10.0%
Average Trading Volume: 4,997,230
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$113.7M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.